Established Medications Combat Lung Cancer Tumor Growth (IMAGE)

American Association for the Advancement of Science (AAAS)

Established Medications Combat Lung Cancer Tumor Growth

Caption

A representation of the EGFR protein, which plays a role in the progression of lung tumors driven by mutations in the KRAS protein. This material relates to a paper that appeared in the 20 June, issue of <i>Science Translational Medicine</i>, published by AAAS. The paper, by H.P. Moll at Medical University of Viennain Vienna, Austria; and colleagues was titled, "Afatinib restrains K-RAS-driven lung tumorigenesis."

Credit

biolution GmbH 2018

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.